SLC6A3 and SLC6A3-related dopamine transporter deficiency syndrome: Our study suggests that mutations in SLC6A3 lead to a continuum of DTDS phenotypes whereby the clinical phenotype appears to be related to residual DAT function, which determines the onset and severity of symptoms.